Structure Therapeutics Inc. American Depositary Shares Dividends

The next dividend date for Structure Therapeutics Inc. American Depositary Shares has not yet been scheduled.

What is a Dividend Date

When we talk about a dividend date, we’re referring specifically to the ex-dividend date.

This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.

The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.

Most brokerages will automatically credit the dividend to your account once it’s issued.

Historical Dividends for Structure Therapeutics Inc. American Depositary Shares (GPCR)

No Results.
DateDeclaration DateRecord DatePayment DateAmount
No Results.

More About Structure Therapeutics Inc. American Depositary Shares

Country
USA
Full Time Employees
199

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Owning Structure Therapeutics Inc. American Depositary Shares Stock on the Dividend Date

If you own Structure Therapeutics Inc. American Depositary Shares stock on the ex-dividend date, then you earn the associated dividend.

Theoretically, the price of Structure Therapeutics Inc. American Depositary Shares stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of Structure Therapeutics Inc. American Depositary Shares stock).

Therefore, it is typically not expected that there is any incremental profit to be gained from buying Structure Therapeutics Inc. American Depositary Shares stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the Structure Therapeutics Inc. American Depositary Shares dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.

Learning More Structure Therapeutics Inc. American Depositary Shares Dividends

You can contact us any time if you would like to ask questions about Structure Therapeutics Inc. American Depositary Shares dividends or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.